UCB (OTCMKTS:UCBJY) Stock Price Down 4.5% – Should You Sell?

UCB SA (OTCMKTS:UCBJY)’s share price traded down 4.5% during mid-day trading on Friday . The stock traded as low as $122.36 and last traded at $122.76. 8,405 shares changed hands during trading, a decline of 78% from the average session volume of 37,645 shares. The stock had previously closed at $128.5750.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Barclays downgraded UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Zacks Research raised UCB from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy”.

UCB Stock Down 4.9%

The company’s 50 day moving average price is $134.39 and its 200-day moving average price is $142.95. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.